A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis. (EXPAND)
|eligibility and information (clinicaltrials.gov)|
Principal Investigator: Allen C. Bowling, MD, PhD
Sub-Investigator: Karen O. Theriot, MD
To speak with someone from CNI research, please call Lenden Neeper at 303-357-5443 or email email@example.com.
People with progressive multiple sclerosis (MS) have limited treatment options compared to non-progressive forms of MS. Research is ongoing to address the need for improved treatments in people experiencing progressing disability due to their MS. We are currently looking for volunteers to participate in EXPAND,*a clinical trial that will evaluate an investigational therapy for secondary-progressive MS.
The EXPAND trial is being conducted by Novartis working in collaboration with researchers around the world. Our goal is to recruit 1530 volunteers with symptoms consistent with secondary-progressive MS from over 30 countries. An individual person’s eligibility for EXPAND will be determined by their age, current state of health, and medical history.
Participants in EXPAND will need to take the investigational drug by mouth daily** and will be examined every 3 months by study staff. About one-third (determined randomly) of people who participate in EXPAND will receive a daily placebo (that is, a pill with no active drug in it) instead of investigational drug. None of the volunteers or researchers will know who has been given the placebo. Talk to your physician about the risks and benefits of participating in a placebo-controlled trial.
Participating in a clinical trial, such as EXPAND, is one way for people with multiple sclerosis to work with doctors and researchers to develop new medicines and potentially change how the disease is treated. If you are interested in learning more about EXPAND, talk to your Lenden Neeper at 303-357-5443 or firstname.lastname@example.org.
WHAT IS SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS?
Multiple sclerosis (MS) is a disease in which the body’s immune system mistakenly attacks the central nervous system; people with MS can have a wide range of symptoms, from mild pain and numbness to severe paralysis and disability.
Most people with MS have relapsing-remitting MS when they are first diagnosed; people with relapsing-remitting MS suffer occasional attacks, called relapses, but often feel better between attacks.
Secondary-progressive MS develops after relapsing-remitting MS.
In secondary-progressive MS, relapses often become less frequent; however disability steadily gets worse.
In time, people with secondary-progressive MS may come to have difficulty with things they are used to doing, like walking; as time goes on, disability may become more severe
WHO GETS SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS?
Secondary-progressive MS usually develops in people who have had relapsing-remitting MS for several years.